Overview
- UC Berkeley researchers reported that oral TOFA caused an average 18% weight loss in obese male mice over four weeks with most loss from fat and without reducing food intake.
- The mice showed up to an 18% rise in whole‑body energy expenditure while activity and body temperature stayed unchanged, and lean mass was largely preserved.
- Lab tests link TOFA to inhibition of acetyl‑CoA carboxylase (ACC) and partial activation of PPARα/δ, actions that appear to slow new fat synthesis and boost fat uptake and burning.
- Combining lower doses of TOFA with GLP‑1 drugs such as semaglutide or tirzepatide produced larger weight and metabolic gains in mice than any single drug alone.
- The findings are preclinical only: TOFA has not been tested in humans, safety, effective dosing and effects in females are unknown, and the team plans further toxicology and larger‑animal studies while two authors hold equity in ReRx Therapeutics.